The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Firing up the cold tumors by targeting Vps34
Open accessAbstract
Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this finding, lysosomotropic agents or small molecules targeting the PtdIns3K PIK3C3/VSP34 have been efficiently combined with therapeutic regimens that promote the activation of the immune system against cancer cells (Janji et al, 2020; Noman et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Janji et al, 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 3×
“Therefore, many ongoing clinical trials in immuno-oncology are focusing on strategies making cold tumors hot, so patients can better benefit from ICB.2 We have previously reported that hypoxia-induced autophagy in tumor cells was associated with tumor resistance to cytotoxic T lymphocyte-3 and natural killer cells (NK…”
BackgroundInfluentialChemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“We next evaluated the expression of several proinflammatory chemokines/cytokines involved in the recruitment of CD8 T cells into human melanomas.(10) Our data indicated that Vps34 inhibition induced the secretion of proinflammatory CCL5, CXCL10, and IFNγ within the tumor microenvironment, most likely generated by mela…”
BackgroundCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“Despite the exciting and encouraging clinical responses obtained, the majority of patients treated with anti-CTLA-4, anti-PD-1, or anti-PD-L1 monotherapy still show none or partial objective responses.(1) Therefore, to achieve durable tumor regression in melanoma and CRC patients, there is a strong need to design new…”
BackgroundAutophagy maintains tumour growth through circulating arginine
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0697-7 · Cited by 360 · cited 1×
“However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of ICB is still poorly explored.(6,7) Vacuolar protein sorting 34 (Vps34), also known as class III phosphoinositide 3-kinase (PIK3C3) is involved in the initiation of autophagy and in the process of endoc…”
BackgroundYang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0952 · Cited by 349 · cited 1×
“However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of ICB is still poorly explored.(6,7) Vacuolar protein sorting 34 (Vps34), also known as class III phosphoinositide 3-kinase (PIK3C3) is involved in the initiation of autophagy and in the process of endoc…”
BackgroundBaginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344 · cited 1×
“We have previously reported that hypoxia-induced autophagy in tumor cells was associated with tumor resistance to cytotoxic T lymphocyte-(3) and natural killer cells (NK)mediated killing.(4) Additionally, we showed that targeting autophagy improved the efficacy of cancer vaccination and promoted tumor regression in me…”
BackgroundSelf-citationNoman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256 · cited 1×
“Additionally, we showed that targeting autophagy improved the efficacy of cancer vaccination and promoted tumor regression in melanoma.(3) We further revealed that silencing the autophagy-related protein Beclin1 decreased tumor growth by inducing a massive infiltration of NK cells through the release of CCL5/RANTES by…”
BackgroundSelf-citationNoman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255 · cited 2×
“By using immunocompromised NOD SCID Gamma (NSG) mice or immunocompetent mice depleted for NK or CD8 cells, we demonstrated that both NK and CD8 T effector cells are the major immune cells controlling the growth of Vps34-targeted B16-F10 tumors.(9) We next evaluated the expression of several proinflammatory chemokines/…”
BackgroundMethodSelf-citationMgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226 · cited 1×
“We further revealed that silencing the autophagy-related protein Beclin1 decreased tumor growth by inducing a massive infiltration of NK cells through the release of CCL5/RANTES by melanoma cells.(5) However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of I…”
BackgroundSelf-citationMarsh, T., & Debnath, J. (2014) · Nature Cell Biology · doi:10.1038/ncb3089 · Cited by 35
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Targeting autophagy in disease: established and new strategies
Kocak, M., Ezazi Erdi, S., Jorba, G., Maestro, I., Farrés, J., Kirkin, V., Martinez, A., & Pless, O. (2022) · Autophagy · doi:10.1080/15548627.2021.1936359 · Cited by 228
“ULK1-ULK2 complex inhibitors: SBI-0206965 was discovered as a small molecule pyrimidine analog ULK1 kinase inhibitor, with biochemical IC50 of 108 nM for ULK1 kinase activity and 711 nM for ULK2 [164].”
BackgroundInfluentialRadiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 213
Recent advances in targeting autophagy in cancer
Jain, V., Singh, M. P., & Amaravadi, R. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.003 · Cited by 151
Autophagy in the cancer-immunity dialogue
Yamazaki, T., Pedro, J. M. B., Galluzzi, L., Kroemer, G., & Pietrocola, F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.003 · Cited by 86
Metadata
- Authors
- Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z.
- Affiliations
- Luxembourg Institute of Health (LU)
- Karolinska Institutet (SE)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Janji, Bassam
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 1809936-1809936
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC7480807
- OpenAlex
- W3081656916
- Cited by
- 30
- References
- 10
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 8 · 2022: 10 · 2021: 7 · 2020: 1
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Luxembourg National Research (C18/BM/12670304/COMBATIC)
- Fondation Cancer Luxembourg (FC/2018/06)
- Kriibskrank Kanner Foundation (2016-08-15)
- Janssen Cilag Pharma
- Roche pharma
- Action LIONS Vaincre le Cancer Luxembourg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Vps34, cold tumors, autophagy, immune checkpoint inhibitors, combination immunotherapy, tumor immune microenvironment, T cell infiltration, melanoma, colorectal cancer
- MeSH terms
- Autophagy-Related Proteins, Humans, Immunologic Factors, Immunotherapy, Melanoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Firing up the cold tumors by targeting Vps34. https://app.cochat.ai/papers/10.1080/2162402x.2020.1809936
- The paper
- Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020). Firing up the cold tumors by targeting Vps34. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1809936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.